At a recent briefing, researchers cited their studies as examples of the advantages of comparative effectiveness research. One study, for example, questioned the effectiveness of proton therapy for the treatment of prostate cancer. Another found that using the monoclonal antibody bevacizumab (Avastin) as a first-line chemotherapy treatment did not improve outcomes for elderly patients with advanced lung cancer.